Lynx1 Capital Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001910456
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2025 · 14 positions · Total reported value $279.23M · Top-10 concentration 98.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 30.3% · 6 new · 2 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -15.3% · vs SPY -17.4% · Prev Value $865.53M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -5.1% · vs SPY -7.2% · Latest Value $646.09M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2025 13F filing, Lynx1 Capital Management LP disclosed 14 equity positions with a combined reported value of $279.23M. The filing implies a focused portfolio: its ten largest positions account for 98.2% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2025 were GHRS ($71.08M), MRUS ($66.03M), PTGX ($35.45M). By sector, the heaviest allocations are Health Care 76.4%, Other 23.6%. Versus the prior quarter, allocation shifted toward Health Care (+3.1pp) and away from Other (-3.1pp).
Versus the prior quarter, Lynx1 Capital Management LP opened 6 new positions, trimmed 2 and fully exited 2, a turnover rate of 30.3% of positions. The portfolio's overlap with the prior quarter was 60% of names.
The largest new positions opened in Q1 2025 were PTGX ($35.45M), DSGN ($254.58K).
Of the 2 positions fully exited versus the prior quarter, the largest were KROS ($8.61M), ALLK ($4.39M), CRBU ($1.08M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2025)
- PTGX PROTAGONIST THERAPEUTICS INC · $35.45M
- DSGN DESIGN THERAPEUTICS INC · $254.58K
Fully Exited (vs previous quarter)
Insider Transactions (Form 4)
Latest Lynx1 Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-26 | Buy | Korro Bio, Inc. | 25,124 | $11.75 | SEC filing |
| 2026-10-23 | Buy | Korro Bio, Inc. | 2,510 | $12.11 | SEC filing |
| 2026-10-22 | Buy | Korro Bio, Inc. | 40,000 | $11.04 | SEC filing |
| 2026-10-22 | Buy | Korro Bio, Inc. | 12,175 | $9.68 | SEC filing |
| 2026-08-10 | Buy | Korro Bio, Inc. | 1,462 | $13.19 | SEC filing |
| 2026-08-06 | Buy | Korro Bio, Inc. | 5,222 | $11.40 | SEC filing |
| 2026-06-25 | Buy | Passage BIO, Inc. | 50,055 | $4.12 | SEC filing |
Fund Profile
Lynx1 Capital Management LP, based in Dorado, PR, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 31 positions worth $646.09M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: DORADO, PR, United States
- SEC registration: 801-127585 (status: Approved), registered 2023-04-05
- Regulatory AUM (Form ADV): $626.68M as of 2026-10-07
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
Portfolio Structure
- 31 positions · $646.09M reported value (Q3 2026)
- Top 10 holdings = 97.9% of reported value
- Largest position: GHRS (GH RESEARCH PLC) at 48.2%
- Average position size: $20.84M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 6 new, 5 added, 2 reduced, 2 exited
- 18 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
6.44M | $71.08M | 25.45% | Add | |
| 2 |
|
1.57M | $66.03M | 23.65% | Reduce | |
| 3 |
|
733.01K | $35.45M | 12.70% | New | |
| 4 |
|
5.29M | $35.19M | 12.60% | Add | |
| 5 |
|
3.22M | $24.34M | 8.72% | Add | |
| 6 |
|
11.06M | $16.14M | 5.78% | Add | |
| 7 |
|
7.10M | $11.36M | 4.07% | Add | |
| 8 |
|
5.36M | $7.39M | 2.65% | Hold | |
| 9 |
|
766.05K | $3.65M | 1.31% | Hold | |
| 10 |
|
862.28K | $3.47M | 1.24% | Hold | |
| 11 |
|
9.26M | $3.27M | 1.17% | Hold | |
| 12 |
|
219.25K | $1.34M | 0.48% | Reduce | |
| 13 |
|
45.81K | $263.84K | 0.09% | Hold | |
| 14 |
|
65.95K | $254.58K | 0.09% | New | |
FAQ
What did Lynx1 Capital Management LP buy in 2025-Q1?
In its 2025-Q1 13F filing, Lynx1 Capital Management LP reported 14 equity positions worth $279.23M in aggregate; its largest disclosed positions were GHRS ($71.08M), MRUS ($66.03M), PTGX ($35.45M).
How large is Lynx1 Capital Management LP's portfolio?
Lynx1 Capital Management LP reported $279.23M of long equity holdings across 14 positions as of 2025-Q1. Top-10 holdings account for 98.2% of reported value.
What is Lynx1 Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.